RBFC
CHRS icon

Roman Butler Fullerton & Co’s Coherus Oncology CHRS Stock Holding History

Roman Butler Fullerton & Co’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,000
Closed -$203K – 162
2019
Q3 		$203K Buy
+10,000
New +$200K 0.14% 161
2019
Q1 		– Sell
-10,000
Closed -$122K – 175
2018
Q4 		$122K Buy
+10,000
New +$116K 0.1% 157

Other funds holding CHRS

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Roman Butler Fullerton & Co's CHRS Position: Q4 2019 in Review

Roman Butler Fullerton & Co sold out of Coherus Oncology (CHRS) in Q4 2019, closing a stake of 10,000 shares — an estimated $203K sold.

Roman Butler Fullerton & Co first reported a position in CHRS in Q4 2018 and held it in 2 quarters. The position peaked at $203K in Q3 2019. 188 funds tracked by Wall St. Rank hold CHRS as of Q4 2019.

  • Roman Butler Fullerton & Co reported no remaining Coherus Oncology position as of Q4 2019 after selling out during the quarter.
  • Roman Butler Fullerton & Co sold 10,000 Coherus Oncology shares in Q4 2019, an estimated $203K.
  • Roman Butler Fullerton & Co first reported a position in Coherus Oncology in Q4 2018 and held it in 2 quarters.
  • Roman Butler Fullerton & Co's Coherus Oncology position peaked at $203K in Q3 2019.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2019.

Based on Roman Butler Fullerton & Co's 13F filing for Q4 2019, filed 27 Jan 2020.